The collateral damage caused by the COVID-19 pandemic influences cardiovascular disease patients, mainly acute coronary syndrome (ACS) cases. Additionally, lockdown has caused treatment-related concerns and reluctance, factors that can delay treatment.
To analyse the incidence and course of ACS patients following the first COVID-19 wave.
The report represents a multi-institutional registry of 10 interventional cardiology departments. ACS patient data were gathered from June to October 2020, the period following the first lockdown in Poland (March 30-May 31, 2020), and compared with the corresponding 2019 timeframe.
Patients (2801 and 2620) hospitalized for ACS in 2019 and 2020 (June-October), represent 52.8% and 57.9% of coronary artery disease admissions, respectively. In 2020 vs. 2019, more cases of arterial hypertension (80.2% vs. 71.5%; P <0.001), diabetes (32.7% vs. 28.2%; P <0.001), hyperlipidaemia (53.2% vs. 49.8%; P = 0.01) and smoking history (29.5% vs. 25.8%; P = 0.003) were detected. Median troponin and cholesterol values, as well as glycemia were higher in 2020. Patients were more likely to undergo percutaneous treatment (91.2% vs. 87.5%; P <0.001) and less often referred for surgery (3.7% vs. 4.9%; P = 0.03). No differences in deaths, repeat myocardial infarction, stroke, and/or composite endpoint (major adverse cardiac and cerebrovascular events [MACCE]) were noted. However, suffering from ACS in 2020 (June-October) was a risk factor for mortality based on a multivariable analysis.
The COVID-19 pandemic affects ACS patient profile, course of treatment, and increases risk for mortality.